466 related articles for article (PubMed ID: 30171558)
1. In Vitro Evaluation of Antisense-Mediated Exon Inclusion for Spinal Muscular Atrophy.
Touznik A; Maruyama R; Yokota T
Methods Mol Biol; 2018; 1828():439-454. PubMed ID: 30171558
[TBL] [Abstract][Full Text] [Related]
2. Systemic and ICV Injections of Antisense Oligos into SMA Mice and Evaluation.
Aslesh T; Maruyama R; Yokota T
Methods Mol Biol; 2018; 1828():455-465. PubMed ID: 30171559
[TBL] [Abstract][Full Text] [Related]
3. Recent Advances and Clinical Applications of Exon Inclusion for Spinal Muscular Atrophy.
Son HW; Yokota T
Methods Mol Biol; 2018; 1828():57-68. PubMed ID: 30171534
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of Exon Inclusion Induced by Splice Switching Antisense Oligonucleotides in SMA Patient Fibroblasts.
Maruyama R; Touznik A; Yokota T
J Vis Exp; 2018 May; (135):. PubMed ID: 29806836
[TBL] [Abstract][Full Text] [Related]
5. Challenges and future perspective of antisense therapy for spinal muscular atrophy: A review.
Nakevska Z; Yokota T
Eur J Cell Biol; 2023 Jun; 102(2):151326. PubMed ID: 37295266
[TBL] [Abstract][Full Text] [Related]
6. Combination of valproic acid and morpholino splice-switching oligonucleotide produces improved outcomes in spinal muscular atrophy patient-derived fibroblasts.
Farrelly-Rosch A; Lau CL; Patil N; Turner BJ; Shabanpoor F
Neurochem Int; 2017 Sep; 108():213-221. PubMed ID: 28389270
[TBL] [Abstract][Full Text] [Related]
7. Morpholino-Mediated Exon Inclusion for SMA.
Zhou H; Muntoni F
Methods Mol Biol; 2018; 1828():467-477. PubMed ID: 30171560
[TBL] [Abstract][Full Text] [Related]
8. Nusinersen in the Treatment of Spinal Muscular Atrophy.
Goodkey K; Aslesh T; Maruyama R; Yokota T
Methods Mol Biol; 2018; 1828():69-76. PubMed ID: 30171535
[TBL] [Abstract][Full Text] [Related]
9. Designing Effective Antisense Oligonucleotides for Exon Skipping.
Shimo T; Maruyama R; Yokota T
Methods Mol Biol; 2018; 1687():143-155. PubMed ID: 29067661
[TBL] [Abstract][Full Text] [Related]
10. Antisense Oligonucleotide Induction of the hnRNPA1b Isoform Affects Pre-mRNA Splicing of
Toosaranont J; Ruschadaariyachat S; Mujchariyakul W; Arora JK; Charoensawan V; Suktitipat B; Palmer TN; Fletcher S; Wilton SD; Mitrpant C
Int J Mol Sci; 2022 Apr; 23(7):. PubMed ID: 35409296
[TBL] [Abstract][Full Text] [Related]
11. Combined treatment with the histone deacetylase inhibitor LBH589 and a splice-switch antisense oligonucleotide enhances SMN2 splicing and SMN expression in Spinal Muscular Atrophy cells.
Pagliarini V; Guerra M; Di Rosa V; Compagnucci C; Sette C
J Neurochem; 2020 Apr; 153(2):264-275. PubMed ID: 31811660
[TBL] [Abstract][Full Text] [Related]
12. Improved antisense oligonucleotide design to suppress aberrant SMN2 gene transcript processing: towards a treatment for spinal muscular atrophy.
Mitrpant C; Porensky P; Zhou H; Price L; Muntoni F; Fletcher S; Wilton SD; Burghes AH
PLoS One; 2013; 8(4):e62114. PubMed ID: 23630626
[TBL] [Abstract][Full Text] [Related]
13. The Antisense Transcript SMN-AS1 Regulates SMN Expression and Is a Novel Therapeutic Target for Spinal Muscular Atrophy.
d'Ydewalle C; Ramos DM; Pyles NJ; Ng SY; Gorz M; Pilato CM; Ling K; Kong L; Ward AJ; Rubin LL; Rigo F; Bennett CF; Sumner CJ
Neuron; 2017 Jan; 93(1):66-79. PubMed ID: 28017471
[TBL] [Abstract][Full Text] [Related]
14. Spinal muscular atrophy: antisense oligonucleotide therapy opens the door to an integrated therapeutic landscape.
Wood MJA; Talbot K; Bowerman M
Hum Mol Genet; 2017 Oct; 26(R2):R151-R159. PubMed ID: 28977438
[TBL] [Abstract][Full Text] [Related]
15. Tips to Design Effective Splice-Switching Antisense Oligonucleotides for Exon Skipping and Exon Inclusion.
Maruyama R; Yokota T
Methods Mol Biol; 2018; 1828():79-90. PubMed ID: 30171536
[TBL] [Abstract][Full Text] [Related]
16. A single administration of morpholino antisense oligomer rescues spinal muscular atrophy in mouse.
Porensky PN; Mitrpant C; McGovern VL; Bevan AK; Foust KD; Kaspar BK; Wilton SD; Burghes AH
Hum Mol Genet; 2012 Apr; 21(7):1625-38. PubMed ID: 22186025
[TBL] [Abstract][Full Text] [Related]
17. High Concentration or Combined Treatment of Antisense Oligonucleotides for Spinal Muscular Atrophy Perturbed
Wijaya YOS; Niba ETE; Nishio H; Okamoto K; Awano H; Saito T; Takeshima Y; Shinohara M
Genes (Basel); 2022 Apr; 13(4):. PubMed ID: 35456491
[TBL] [Abstract][Full Text] [Related]
18. Potential of Cell-Penetrating Peptide-Conjugated Antisense Oligonucleotides for the Treatment of SMA.
Leckie J; Yokota T
Molecules; 2024 Jun; 29(11):. PubMed ID: 38893532
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of Cell-Penetrating Peptide Delivery of Antisense Oligonucleotides for Therapeutic Efficacy in Spinal Muscular Atrophy.
Hammond SM; Abendroth F; Gait MJ; Wood MJA
Methods Mol Biol; 2019; 2036():221-236. PubMed ID: 31410800
[TBL] [Abstract][Full Text] [Related]
20. 5-(N-ethyl-N-isopropyl)-amiloride enhances SMN2 exon 7 inclusion and protein expression in spinal muscular atrophy cells.
Yuo CY; Lin HH; Chang YS; Yang WK; Chang JG
Ann Neurol; 2008 Jan; 63(1):26-34. PubMed ID: 17924536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
